Autism Research and Treatment / 2012 / Article / Tab 3

Research Article

Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism

Table 3

Language and autism behavior ratings over the course of the study for each study participant.

IDExpressive LanguageReceptive LanguageChildhood Autism Rating Scale*
BaselineWeek 6Week 12BaselineWeek 6Week 12BaselineWeek 6Week 12

10.00.00.09.010.05.051.051.051.0
21.01.02.014.013.020.044.043.043.0
385.067.076.072.079.060.033.030.027.0
438.036.038.027.036.046.042.041.539.0
535.046.048.049.035.033.0
60.00.039.5
759.065.062.067.039.533.5

𝑃 value*†1.00na††0.110na††0.0430.109

* Decreasing scores reflect increased improvement.
𝑃 values represent the results of the differences between baseline values and 6 and 12-month values using the Wilcoxon Signed Ranks Test.
†† Insufficient data to compute.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.